CONSOLIDATED STATEMENTS OF (LOSS) INCOME (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues
Product sales	$ 5,640,333	$ 3,288,592	$ 2,255,050
Alliance and royalty	52,606	105,591	136,473
Service and other	76,666	86,193	35,927
Total revenues	5,769,605	3,480,376	2,427,450
Expenses
Cost of goods sold (exclusive of amortization of intangible assets shown separately below)	1,846,314	905,095	683,750
Cost of alliance and service revenues	58,806	64,601	12,348
Selling, general and administrative	1,305,164	756,083	572,472
Research and development	156,783	79,052	65,687
Amortization and impairments of finite-lived intangible assets (see Note 12)	1,901,977	928,885	557,814
Restructuring, integration and other costs	514,825	344,387	97,667
In-process research and development impairments and other charges	153,639	189,901	109,200
Acquisition-related costs	36,416	78,604	32,964
Acquisition-related contingent consideration	(29,259)	(5,266)	(10,986)
Other expense	234,442	59,349	6,575
Total expenses	6,179,107	3,400,691	2,127,491
Operating (loss) income	(409,502)	79,685	299,959
Interest income	8,023	5,986	4,084
Interest expense	(844,316)	(481,596)	(334,526)
Loss on extinguishment of debt	(65,014)	(20,080)	(36,844)
Foreign exchange and other	(9,465)	19,721	26,551
Gain on investments, net	5,822	2,056	22,776
Loss before recovery of income taxes	(1,314,452)	(394,228)	(18,000)
Recovery of income taxes	(450,783)	(278,203)	(177,559)
Net (loss) income	(863,669)	(116,025)	159,559
Less: Net income attributable to noncontrolling interest	2,473	0	0
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ (866,142)	$ (116,025)	$ 159,559
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (loss) earnings per share (in dollars per share)	$ (2.70)	$ (0.38)	$ 0.52
Diluted (loss) earnings per share (in dollars per share)	$ (2.70)	$ (0.38)	$ 0.49
Weighted-average common shares (000's)
Basic (in shares)	320,996	305,446	304,655
Diluted (in shares)	320,996	305,446	326,119